Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The companyâs lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļāļ·āđāļāļāļĢāļīāļĐāļąāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ- -
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒ- -
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļ- -
āļāļĩāđāļāļĒāļđāđ- -
āđāļĄāļ·āļāļ- -
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđ- -
āļāļĢāļ°āđāļāļĻ- -
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ- -
āđāļāļĢāļĻāļąāļāļāđ- -
āđāļ§āđāļāđāļāļāđ- -
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļ- -
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļ- -
āļāļĩāļāļĩāđāļ- -
Mr. Mark J. Rosenblum, CPA
Mr. Mark J. Rosenblum, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Mr. Peter Marschel
Chief Business Officer
Ms. Tess Burleson
Independent Director
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Independent Director
Dr. William K. McVicar, Ph.D.
Dr. William K. McVicar, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
Mr. David J. Arthur
Director
Dr. Paul I. Lammers, M.D.
Dr. Paul I. Lammers, M.D.
Independent Director
Mr. Arnold C. Hanish
Independent Director
Ms. Maureen McEnroe
IR Contact Officer
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Mark J. Rosenblum, CPA
Mr. Mark J. Rosenblum, CPA
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Mr. Peter Marschel
Chief Business Officer
Ms. Tess Burleson
Independent Director
Mr. Jonathan I. (Jon) Lieber
Mr. Jonathan I. (Jon) Lieber
Independent Director
Dr. William K. McVicar, Ph.D.
Dr. William K. McVicar, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board